These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 15703366

  • 1. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
    Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, Ruus P, Preiss R.
    J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
    [Abstract] [Full Text] [Related]

  • 2. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers.
    Teichert J, Hermann R, Ruus P, Preiss R.
    J Clin Pharmacol; 2003 Nov; 43(11):1257-67. PubMed ID: 14551180
    [Abstract] [Full Text] [Related]

  • 3. Accumulation of vitamin E metabolites in the blood of renal failure patients.
    Galli F, Floridi AG, Floridi A, Buoncristiani U.
    Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of anakinra in subjects with different levels of renal function.
    Yang BB, Baughman S, Sullivan JT.
    Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
    [Abstract] [Full Text] [Related]

  • 5. Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers.
    Teichert J, Kern J, Tritschler HJ, Ulrich H, Preiss R.
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):625-8. PubMed ID: 9876998
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL.
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [Abstract] [Full Text] [Related]

  • 7. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G, Gajjar D, Swan S, Marbury T, Grasela DM, Wang Z.
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [Abstract] [Full Text] [Related]

  • 8. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S, Orlando R, Bertoli M, Pegoraro P, Palatini P.
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB, Dowell JA, Pratt RD.
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
    Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S.
    Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
    [Abstract] [Full Text] [Related]

  • 11. Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.
    Bevan EG, McInnes GT, Aldigier JC, Conte JJ, Grunfeld JP, Harper SJ, Meyer BH, Pauly N, Wilkinson R.
    Br J Clin Pharmacol; 1993 Feb; 35(2):128-35. PubMed ID: 8443030
    [Abstract] [Full Text] [Related]

  • 12. Bromfenac disposition in patients with impaired kidney function.
    Ermer JC, Boni JP, Cevallos WH, DeCleene S, Burghart P, Rudnick MR, Fruncillo RJ, Berns JS, Cohen RM.
    Clin Pharmacol Ther; 1997 Mar; 61(3):312-8. PubMed ID: 9084456
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of repaglinide in subjects with renal impairment.
    Marbury TC, Ruckle JL, Hatorp V, Andersen MP, Nielsen KK, Huang WC, Strange P.
    Clin Pharmacol Ther; 2000 Jan; 67(1):7-15. PubMed ID: 10668848
    [Abstract] [Full Text] [Related]

  • 14. The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance.
    Xiang GD, Sun HL, Zhao LS, Hou J, Yue L, Xu L.
    Clin Endocrinol (Oxf); 2008 May; 68(5):716-23. PubMed ID: 18070144
    [Abstract] [Full Text] [Related]

  • 15. Soluble receptor for advanced glycation end products in patients with decreased renal function.
    Kalousová M, Hodková M, Kazderová M, Fialová J, Tesar V, Dusilová-Sulková S, Zima T.
    Am J Kidney Dis; 2006 Mar; 47(3):406-11. PubMed ID: 16490618
    [Abstract] [Full Text] [Related]

  • 16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 17. Effect of renal function on the pharmacokinetics of palifermin.
    Gillespie B, Zia-Amirhosseini P, Salfi M, Kakkar T, Wang J, Gupta S, Smith B, Robson R, Sullivan JT.
    J Clin Pharmacol; 2006 Dec; 46(12):1460-8. PubMed ID: 17101745
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of ofloxacin in severe chronic renal failure.
    Bandai H, Tsubakihara Y, Yamato E, Yokoyama K, Okada N, Nakanishi I, Iida N.
    Clin Ther; 1989 Dec; 11(2):210-8. PubMed ID: 2736567
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A, Ventura D, Rao N, Abramowitz W.
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [Abstract] [Full Text] [Related]

  • 20. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.
    Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA.
    J Pharm Pharmacol; 2005 Nov; 57(11):1407-13. PubMed ID: 16259772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.